European Journal of Clinical Microbiology

, Volume 5, Issue 2, pp 241–243 | Cite as

Ciprofloxacin in the treatment of acute bacterial diarrhea: A double blind study

  • H. Pichler
  • G. Diridl
  • D. Wolf
Articles Ciprofloxacin: Clinical Experience


In a double-blind, randomized, placebo-controlled trial 50 adult patients with acute diarrhea received either 500 mg ciprofloxacin b.i.d. or a placebo for five days. Results were evaluated in 21 patients in the ciprofloxacin group (10 withSalmonella spp., 11 withCampylobacter jejuni) and 25 patients in the placebo group (16with Salmonella spp., 5 withCampylobacter jejuni, 4 withShigella spp.). The duration of fever in patients treated with ciprofloxacin was 1.5 days versus 2.3 days in the placebo group; the difference was not statistically significant. The duration of diarrhea in the ciprofloxacin group was 1.4 days versus 2.6 days in the placebo group (p < 0.01); the corresponding figures in patients with salmonellosis were 1.6 versus 3.2 (p=0.01). In the ciprofloxacin group all stool cultures became negative 48 h after start of treatment und remained negative during the follow-up period of three weeks. In the placebo group only one of the 25 patients had negative stool cultures during therapy and only seven after the treatment period (p < 0.001). Ciprofloxacin was very well tolerated and was found to be a safe compound without major adverse effects.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Aserkoff, B., Bennett, J. V.: Effect of antibiotic therapy in acute salmonellosis on the faecal excretion of salmonellae. New England Journal of Medicine 1969, 281: 636–640.PubMedCrossRefGoogle Scholar
  2. 2.
    Dixon, J. S.: Effect of antibiotic treatment on duration of excretion ofSalmonella typhi murium by children. British Medical Journal 1965, ii: 1343–1345.CrossRefGoogle Scholar
  3. 3.
    Joiner, K. A., Gorbach, S. L.: Indications for antimicrobial therapy of gastrointestinal disorders. In: Weinstein, L., Fields, B. N. (ed.): Seminars in infectious disease. Volume III. Thieme-Stratton, New York, 1980, p. 153–192.Google Scholar
  4. 4.
    O Hare, M. D., Flemingham, D., Ridgway, G. L., Grüneberg, R. N.: The comparative in vitro activity of twelve 4-quinolone antimicrobials against enteric pathogens. Drugs under Experimental and Clinical Research 1985, 11: 253–257.PubMedGoogle Scholar
  5. 5.
    Diez-Enciso, M., Mas-Jimenez, G., Velasco-Cerrudo, A., Guiterrez-Altes, A.: Comparison of the in vitro activity of ciprofloxacin (Bay 09867) and norfloxacin against gastrointestinal tract pathogens. European Journal of Clinical Microbiology 1984, 3: 367.CrossRefPubMedGoogle Scholar
  6. 6.
    Smith, J. T.: Chemistry and mode of action of 4-quinolone agents. Fortschritte der antimikrobiellen und antineoplastischen Chemotherapie 1984, 3–5: 493–508.Google Scholar

Copyright information

© Friedr. Vieweg & Sohn 1986

Authors and Affiliations

  • H. Pichler
    • 1
  • G. Diridl
    • 1
  • D. Wolf
    • 2
  1. 1.Department of Infectious DiseasesKaiser Franz Josef-HospitalViennaAustria
  2. 2.Institute of BacteriologyKaiser Franz Josef-HospitalViennaAustria

Personalised recommendations